Investigative Magnetic Resonance Imaging

Korean Society of Magnetic Resonance in Medicine (대한자기공명의과학회)
권호 표지
DOI QR코드

DOI QR Code

Multifocal Extranodal Involvement in Diffuse Large B-cell Lymphoma (DLBCL): Bone, Soft tissue, Testis, and Kidney

  • Cho, Jae Sung (Department of Radiology, Jeju National University Hospital) ;
  • Lee, Kyung Ryeol (Department of Radiology, Jeju National University Hospital) ;
  • Kim, Bong Soo (Department of Radiology, Jeju National University Hospital) ;
  • Choi, Guk Myung (Department of Radiology, Jeju National University Hospital) ;
  • Lee, Jeong Sub (Department of Radiology, Jeju National University Hospital) ;
  • Huh, Jung Sik (Department of Urology, Jeju National University Hospital) ;
  • Jang, Bogun (Department of Pathology, Jeju National University Hospital)
  • Received : 2021.07.30
  • Accepted : 2021.10.14
  • Published : 2022.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

In this report we present a case of disseminated diffuse large B-cell lymphoma (DLBCL) in a 79-year-old man affecting the bone, soft tissue, testis, and both kidneys, which are rarely affected sites. The formation of a large mass in the bone, soft tissue, and testis due to DLBCL is rarely seen nowadays. In this article, we describe the imaging findings and clinical significance of multifocal extranodal involvement in DLBCL, focusing on involvement of bone, soft tissue, and testis.

Keywords

References

  1. Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012;118:4166-4172 https://doi.org/10.1002/cncr.27381
  2. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068 https://doi.org/10.1200/JCO.2013.54.8800
  3. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842 https://doi.org/10.1182/blood-2013-09-524108
  4. Chun CW, Jee WH, Park HJ, et al. MRI features of skeletal muscle lymphoma. AJR Am J Roentgenol 2010;195:1355-1360 https://doi.org/10.2214/AJR.09.3904
  5. Lim CY, Ong KO. Imaging of musculoskeletal lymphoma. Cancer Imaging 2013;13:448-457 https://doi.org/10.1102/1470-7330.2013.0036
  6. Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol 2009;27:5227-5232 https://doi.org/10.1200/JCO.2009.22.5896
  7. Zicherman JM, Weissman D, Gribbin C, Epstein R. Best cases from the AFIP: primary diffuse large B-cell lymphoma of the epididymis and testis. Radiographics 2005;25:243-248 https://doi.org/10.1148/rg.251045041
  8. Mayerhoefer ME, Karanikas G, Kletter K, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 2014;20:2984-2993 https://doi.org/10.1158/1078-0432.CCR-13-3355
  9. Wang D, Huo Y, Chen S, et al. Whole-body MRI versus (18)F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis. Onco Targets Ther 2018;11:3597-3608 https://doi.org/10.2147/OTT.S148189
  10. Kim SH. Collison tumor of adenocarcinoma and diffuse large B-cell lymphoma in the rectum: a case report and literature review. Investig Magn Reson Imaging 2019;23:374-380 https://doi.org/10.13104/imri.2019.23.4.374